Andreas Mueller

632 total citations
24 papers, 241 citations indexed

About

Andreas Mueller is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Andreas Mueller has authored 24 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in Andreas Mueller's work include Cancer Treatment and Pharmacology (5 papers), Advanced Breast Cancer Therapies (4 papers) and Breast Cancer Treatment Studies (4 papers). Andreas Mueller is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Advanced Breast Cancer Therapies (4 papers) and Breast Cancer Treatment Studies (4 papers). Andreas Mueller collaborates with scholars based in Germany, Switzerland and Austria. Andreas Mueller's co-authors include Volker Klauß, Mike P. Holzer, Gerd U. Auffarth, Bettina Thomas, Christoph Rochlitz, Hanne Hawle, William R. Freeman, B. Bubeck, Karl Y. Hostetler and James R. Beadle and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Andreas Mueller

23 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andreas Mueller Germany	10	67	66	57	53	46	24	241
Huiqiang Liu China	11	24 0.4×	11 0.2×	6 0.1×	108 2.0×	72 1.6×	31	285
José María Sánchez‐Pina Spain	8	112 1.7×	44 0.7×	40 0.7×	71 1.3×	30 0.7×	25	270
J. A. Holmes United Kingdom	8	161 2.4×	34 0.5×	29 0.5×	126 2.4×	19 0.4×	13	357
Matt Church United Kingdom	4	73 1.1×	12 0.2×	4 0.1×	112 2.1×	19 0.4×	5	350
Ilkka Raivio Finland	10	71 1.1×	94 1.4×	387 6.8×	47 0.9×	46 1.0×	14	416
Marcel Costa-García Spain	11	119 1.8×	7 0.1×	16 0.3×	46 0.9×	120 2.6×	21	398
Xiang Yin United States	8	37 0.6×	16 0.2×	4 0.1×	34 0.6×	25 0.5×	15	373
Jessica D. St. Laurent United States	9	49 0.7×	9 0.1×	2 0.0×	114 2.2×	69 1.5×	19	296
Gösta Magnusson Sweden	9	31 0.5×	13 0.2×	7 0.1×	139 2.6×	29 0.6×	18	353
Felipe Sandoval United States	11	67 1.0×	6 0.1×	13 0.2×	89 1.7×	96 2.1×	19	340

Countries citing papers authored by Andreas Mueller

Since Specialization

Citations

This map shows the geographic impact of Andreas Mueller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Mueller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Mueller more than expected).

Fields of papers citing papers by Andreas Mueller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Mueller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Mueller. The network helps show where Andreas Mueller may publish in the future.

Co-authorship network of co-authors of Andreas Mueller

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Mueller. A scholar is included among the top collaborators of Andreas Mueller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Mueller. Andreas Mueller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mueller, Andreas, Stefanie Hayoz, Michael Mark, et al.. (2024). Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w).. Journal of Clinical Oncology. 42(16_suppl). 12067–12067.

Weber, William P., Stefanie Hayoz, Christoph Tausch, et al.. (2024). Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (OPBC-03/SAKK 23/16/IBCSG 57-18/ABCSG-53/GBG-101-TAXIS).. Journal of Clinical Oncology. 42(16_suppl). TPS611–TPS611. 1 indexed citations

Krentel, Harald, J. Keckstein, O. Buchweitz, et al.. (2023). Accuracy of ultrasound signs on two‐dimensional transvaginal ultrasound in prediction of adenomyosis: prospective multicenter study. Ultrasound in Obstetrics and Gynecology. 62(5). 739–746. 14 indexed citations

Mueller, Andreas, Qiyu Li, Beat Thuerlimann, et al.. (2022). Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]. Journal of Geriatric Oncology. 14(1). 101372–101372. 1 indexed citations

Heinzelmann‐Schwarz, Viola, Christian Kurzeder, Seraina Schmid, et al.. (2021). ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low-Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer—A randomized, double-blinded, placebo-controlled, multicenter phase III Trial.. Journal of Clinical Oncology. 39(15_suppl). TPS5598–TPS5598. 6 indexed citations

Klafke, Nadja, Cornelia Mahler, Cornelia von Hagens, et al.. (2019). The effects of an integrated supportive care intervention on quality of life outcomes in outpatients with breast and gynecologic cancer undergoing chemotherapy: Results from a randomized controlled trial. Cancer Medicine. 8(8). 3666–3676. 22 indexed citations

Pestalozzi, Bernhard C., Christoph Tausch, Konstantin J. Dedes, et al.. (2017). Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC Cancer. 17(1). 265–265. 10 indexed citations

Thomas, Bettina, Andreas Mueller, Gerd U. Auffarth, & Mike P. Holzer. (2016). Influence on intraocular lens power calculation of corneal radii measurement using an image-guided system. Journal of Cataract & Refractive Surgery. 42(11). 1588–1594. 4 indexed citations

Mueller, Andreas, Bettina Thomas, Gerd U. Auffarth, & Mike P. Holzer. (2016). Comparison of a new image-guided system versus partial coherence interferometry, Scheimpflug imaging, and optical low-coherence reflectometry devices: Keratometry and repeatability. Journal of Cataract & Refractive Surgery. 42(5). 672–678. 19 indexed citations

10.

Zaman, Khalil, Christoph Mamot, Christoph Rochlitz, et al.. (2015). Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. European Journal of Cancer. 51(10). 1212–1220. 43 indexed citations

11.

Ruhstaller, Thomas, Karin Ribi, Hong Sun, et al.. (2012). Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase lll trial (SAKK 92/08).. Journal of Clinical Oncology. 30(15_suppl). 9059–9059. 4 indexed citations

12.

Essue, Beverley M., et al.. (2011). inVestIgating the pSychologIcal and ecONomic impAct of cataRact surgerY in Vietnam: The VISIONARY observational study protocol. BMC Ophthalmology. 11(1). 25–25. 5 indexed citations

13.

Moehler, Markus, Andreas Mueller, S-E. Al-Batran, et al.. (2011). An open-label, multicenter biomarker-oriented phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Zeitschrift für Gastroenterologie. 49(8). 2 indexed citations

14.

Klaeser, Bernd, et al.. (2007). Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Annals of Oncology. 18(8). 1329–1334. 22 indexed citations

15.

Haritoglou, Christos & Andreas Mueller. (2003). Visusanstieg nach Chemotherapie einer Aderhautmetastase eines Mammakarzinoms. Der Ophthalmologe. 100(4). 326–329. 5 indexed citations

16.

Mueller, Andreas, et al.. (1994). [HIV-1 and tears. Results of virus isolation and polymerase chain reaction (PCR)].. PubMed. 91(5). 663–7. 2 indexed citations

17.

Mueller, Andreas & Volker Klauß. (1993). Main sources of infection in 145 cases of epidemic keratoconjunctivitis.. PubMed. 2(4-5). 224–7. 16 indexed citations

18.

Mueller, Andreas, et al.. (1992). Infrequent detection of HIV-1 components in tears compared to blood of HIV-1-infected persons. Infection. 20(5). 249–252. 3 indexed citations

19.

Geier, S, Lutz Gürtler, Volker Klauß, et al.. (1992). Unterschiede in der Nachweisbarkeit von Humanem Immunschwäche Virus Typ 1 in Tränenflüssigkeit und Blutlymphozyten. Klinische Monatsblätter für Augenheilkunde. 201(9). 164–168. 1 indexed citations

20.

Mueller, Andreas, et al.. (1991). [Electro-ophthalmologic studies in HIV patients].. PubMed. 88(6). 712–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact